CHMP has advised that Alhemo be approved for people with severe hemophilia A and moderate or severe hemophilia B without inhibitors.

In July 2025, CSL Behring conducted a study in China is to investigate the pharmacokinetics (PK) of rVIII-SingleChain after ...

There are a couple categories of conditions that can manifest with random bruising—though they typically surface with other ...